Literature DB >> 29917192

MiR-4299 suppresses non-small cell lung cancer cell proliferation, migration and invasion through modulating PTEN/AKT/PI3K pathway.

W-B Yang1, W-P Zhang, J-L Shi, J-W Wang.   

Abstract

OBJECTIVE: The aim of the present study was to investigate clinical significances and biological roles of miR-4299 in non-small cell lung cancer (NSCLC) PATIENTS AND METHODS: Expression of miR-4299 in NSCLC tissues and matched non-tumor tissues was determined by quantitative real-time PCR (qRT-PCR). The correlations between miR-4299 expression and clinicopathological characteristics and prognosis were also analyzed. MTT assay and Transwell assay were performed to determine the proliferation, migration and invasion. Western blotting was used to examine the expressing patterns of PTEN/AKT/PI3K signaling pathway-related proteins.
RESULTS: We found that the expression level of miR-4299 was downregulated in NSCLC tissues and cell lines. Low miR-4299 expression was positively correlated with TNM stage (p=0.002), histological grade (p=0.002) and lymph node metastasis (p=0.028). Moreover, Kaplan-Meier survival analysis showed that the patients with low miR-4299 expression had shorter survival time than those with high miR-4299 expression (p=0.0011). More importantly, multivariate analysis suggested that decreased miR-4299 expression was a poor independent prognostic predictor for NSCLC patients (p=0.009). Functionally, overexpression of miR-4299 inhibited the proliferation, migration and invasion in A549 cells. Mechanistically, the results of Western blot showed that miR-4299 exhibited its tumor-suppressive role by modulating PTEN/AKT/PI3K signaling pathway.
CONCLUSIONS: We firstly indicated that miR-4299 may be a candidate independent marker for NSCLC prognosis and suppressed the progression of NSCLC by modulating the activation of PTEN/AKT/PI3K signaling pathway, suggesting that miR-4299 could be a potential target for developing therapies in treating NSCLC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29917192     DOI: 10.26355/eurrev_201806_15163

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  Effect of miR-126 on the Proliferation and Migration of Vascular Smooth Muscle Cells in Aortic Aneurysm Mice Under PI3K/AKT/mTOR Signaling Pathway.

Authors:  Changpin Huang; Xin Fang; Xupin Xie; Yongchang Liu; Dong Xu; Xiaohu Meng; Jianyun Long
Journal:  Mol Biotechnol       Date:  2021-05-10       Impact factor: 2.695

2.  Silencing of BRF2 inhibits the growth and metastasis of lung cancer cells.

Authors:  Yuan Bian; Qiu Li; Qiaolian Li; Ruigen Pan
Journal:  Mol Med Rep       Date:  2020-06-26       Impact factor: 2.952

3.  MiR-214 Mediates Cell Proliferation and Apoptosis of Nasopharyngeal Carcinoma Through Targeting Both WWOX and PTEN.

Authors:  Ji-Bo Han; Mao-Ling Huang; Fen Li; Rui Yang; Shi-Ming Chen; Ze-Zhang Tao
Journal:  Cancer Biother Radiopharm       Date:  2020-02-26       Impact factor: 3.099

Review 4.  Small in Size, but Large in Action: microRNAs as Potential Modulators of PTEN in Breast and Lung Cancers.

Authors:  Asal Jalal Abadi; Ali Zarrabi; Mohammad Hossein Gholami; Sepideh Mirzaei; Farid Hashemi; Amirhossein Zabolian; Maliheh Entezari; Kiavash Hushmandi; Milad Ashrafizadeh; Haroon Khan; Alan Prem Kumar
Journal:  Biomolecules       Date:  2021-02-18

5.  A microRNA Prognostic Signature in Patients with Diffuse Intrinsic Pontine Gliomas through Non-Invasive Liquid Biopsy.

Authors:  Maria F Iannó; Veronica Biassoni; Elisabetta Schiavello; Andrea Carenzo; Luna Boschetti; Lorenza Gandola; Barbara Diletto; Edoardo Marchesi; Claudia Vegetti; Alessandra Molla; Christof M Kramm; Dannis G van Vuurden; Patrizia Gasparini; Francesca Gianno; Felice Giangaspero; Piergiorgio Modena; Brigitte Bison; Andrea Anichini; Sabina Vennarini; Emanuele Pignoli; Maura Massimino; Loris De Cecco
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

6.  Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.

Authors:  Sha-Sha Wang; Fang Wang; Zhen Zeng; Fang Gao; Huan-Huan Liu; Hui-Na Wang; Yi Hu; Hai-Feng Qin
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

7.  Circular RNA-9119 suppresses in ovarian cancer cell viability via targeting the microRNA-21-5p-PTEN-Akt pathway.

Authors:  Jianming Gong; Xiaoyang Xu; Xuanli Zhang; Yingqiao Zhou
Journal:  Aging (Albany NY)       Date:  2020-07-16       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.